Clinical Research Directory

Inclusion Criteria: * Female patients aged 18-70 years. * ECOG score must be 0 or 1. * Patients with clinical stage II to III new breast cancer, all diagnosed by hollow-core needle aspiration biopsy pathological histology prior to treatment and surgically resectable breast cancer with positive immunohistochemical staining (IHC) for HER2 (3+) or HER2 (2+) supplemented with fluorescence in situ hybridization technique (FISH). * The presence of at least one measurable lesion according to RECIST 1.1 criteria. * Exclusion of distant metastases by abdominal B-ultrasound, chest X-ray and whole-body bone scan prior to neoadjuvant chemotherapy, and for lymph nodes in the enlarged area fine needle aspiration cytology is required to clarify the presence of tumor metastases without a history of remaining malignancies. * Expected survival of not less than 12 weeks. * No previous treatment, including chemotherapy, radiotherapy, targeted therapy, and biologic therapy. -Exclusion Criteria Exclusion Criteria: * Female patients of childbearing age who are pregnant, breastfeeding, or unwilling to use effective contraception throughout the trial period. * Patients with combined severe cardiac, hepatic, renal, or endocrine system diseases and with expected survival of \< 2 years for the above diseases. * Inability to swallow, intestinal obstruction, the presence of other factors affecting drug administration and absorption or a history of allergy to this drug * Karnofsky scale score below 60 * Patients with metastatic breast cancer or bilateral breast cancer. * Patients with inflammatory breast cancer. * Those with a left ventricular ejection fraction (LVEF) \<55% on echocardiography * Those who are deemed by the personnel to be otherwise unsuitable for clinical trials.